Hiroshi Keino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroshi Keino has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Takayo Watanabe
Department of Ophthalmology Kyorin University School of Medicine Tokyo Japan
8 shared publicationsAnnabelle A. Okada
Department of Ophthalmology Kyorin University School of Medicine Tokyo Japan
7 shared publicationsYasuhiko Sato
Department of Ophthalmology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan
6 shared publicationsAkito Hirakata
Department of Ophthalmology, Kyorin University School of Medicine, Tokyo 181‑8611, Japan
3 shared publications- Annabelle Ayame Okada
Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan
3 shared publications Kazuo Umezawa
Department of Molecular Target Medicine Screening, Aichi Medical University, Nagakute, Aichi 480‑1195, Japan
3 shared publications
Latest Publications
- 17 July 2026
- Published by Springer Nature in Documenta Ophthalmologica
- p. 1-8
Electronegative ERG in association with probable TRPM1-related cancer associated retinopathy: a case report
Purpose To describe a patient with electronegative ERGs in association with probable TRPM1-related cancer associated retinopathy. Methods A 67-year-old female presented with progressive visual disturbances, including night blindness, cloudy vision, color vison problems, and scotomas. Initial ophthalmic examination revealed mild retinal vasculitis and an epiretinal membrane in one eye. Visual acuity was bilaterally normal. Electroretinography (ERG) showed electronegative waveforms. Subsequent systemic investigation revealed a lung mass, later confirmed to be a small cell carcinoma, with metastases. Western blot analysis and immunohistochemistry were performed. The patient received cisplatin and etoposide chemotherapy, and sub-Tenon triamcinolone injections (STTA). Results ERGs showed an electronegative waveform with features suggesting pan-retinal loss of On-bipolar cell function. Serum Western blot analysis and immunohistochemistry identified anti-retinal autoantibodies to TRPM1 with binding specificity to the C-terminal region. Further systemic evaluation detected a lung mass, which was later confirmed as small cell lung cancer with metastases. Although initial visual field deterioration was noted, subsequent follow-up showed almost total improvement in visual function, including ERG recovery. Best-corrected visual acuity remained stable at 20/20. Despite the ocular improvements, the patient succumbed to her systemic illness 29 months after the initial visit. Conclusion Electronegative ERGs are unusual in CAR, which usually affects photoreceptor function. This case, associated with anti-retinal autoantibodies to TRPM1, highlights the need for full systems review in a patient with possible paraneoplastic disease, even in the absence of systemic symptoms.
- 17 July 2026
- Published by Springer Nature in Documenta Ophthalmologica
- p. 1-8
Electronegative ERG in association with probable TRPM1-related cancer associated retinopathy: a case report
Purpose To describe a patient with electronegative ERGs in association with probable TRPM1-related cancer associated retinopathy. Methods A 67-year-old female presented with progressive visual disturbances, including night blindness, cloudy vision, color vison problems, and scotomas. Initial ophthalmic examination revealed mild retinal vasculitis and an epiretinal membrane in one eye. Visual acuity was bilaterally normal. Electroretinography (ERG) showed electronegative waveforms. Subsequent systemic investigation revealed a lung mass, later confirmed to be a small cell carcinoma, with metastases. Western blot analysis and immunohistochemistry were performed. The patient received cisplatin and etoposide chemotherapy, and sub-Tenon triamcinolone injections (STTA). Results ERGs showed an electronegative waveform with features suggesting pan-retinal loss of On-bipolar cell function. Serum Western blot analysis and immunohistochemistry identified anti-retinal autoantibodies to TRPM1 with binding specificity to the C-terminal region. Further systemic evaluation detected a lung mass, which was later confirmed as small cell lung cancer with metastases. Although initial visual field deterioration was noted, subsequent follow-up showed almost total improvement in visual function, including ERG recovery. Best-corrected visual acuity remained stable at 20/20. Despite the ocular improvements, the patient succumbed to her systemic illness 29 months after the initial visit. Conclusion Electronegative ERGs are unusual in CAR, which usually affects photoreceptor function. This case, associated with anti-retinal autoantibodies to TRPM1, highlights the need for full systems review in a patient with possible paraneoplastic disease, even in the absence of systemic symptoms.
- Open Access
- 10 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2) , e103392
Spontaneous Regression of a Retinal Mass With Epstein-Barr Virus-Positive and Cytomegalovirus-Positive Panuveitis in Methotrexate-Associated Lymphoproliferative Disorder
Methotrexate (MTX) has been widely used for patients with autoimmune diseases as a corticosteroid-sparing agent. We here report an 86-year-old Japanese woman treated with MTX for rheumatoid arthritis who presented with panuveitis along with a yellowish retinal mass. Both Epstein-Barr virus (EBV) and cytomegalovirus (CMV) were detected in aqueous humor and vitreous fluid by quantitative polymerase chain reaction. The retinal mass gradually regressed over eight months after MTX withdrawal. The present case indicates that intraocular MTX-lymphoproliferative disorder (MTX-LPD) should be considered in the differential diagnosis of patients presenting with uveitis who are undertaking long-term MTX therapy. Multiplex PCR along with quantitative PCR for intraocular fluids may be helpful for understanding the pathogenesis of intraocular MTX-LPD.
- 10 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2) , e103392
Open AccessSpontaneous Regression of a Retinal Mass With Epstein-Barr Virus-Positive and Cytomegalovirus-Positive Panuveitis in Methotrexate-Associated Lymphoproliferative Disorder
Methotrexate (MTX) has been widely used for patients with autoimmune diseases as a corticosteroid-sparing agent. We here report an 86-year-old Japanese woman treated with MTX for rheumatoid arthritis who presented with panuveitis along with a yellowish retinal mass. Both Epstein-Barr virus (EBV) and cytomegalovirus (CMV) were detected in aqueous humor and vitreous fluid by quantitative polymerase chain reaction. The retinal mass gradually regressed over eight months after MTX withdrawal. The present case indicates that intraocular MTX-lymphoproliferative disorder (MTX-LPD) should be considered in the differential diagnosis of patients presenting with uveitis who are undertaking long-term MTX therapy. Multiplex PCR along with quantitative PCR for intraocular fluids may be helpful for understanding the pathogenesis of intraocular MTX-LPD.
- 15 June 2022
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 50 (6) , 685-687
Compromised blood flow of the optic nerve head in acute retinal necrosis
- 15 June 2022
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 50 (6) , 685-687
Compromised blood flow of the optic nerve head in acute retinal necrosis
- 5 May 2022
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 50 (6) , 678-680
Prognostic value of subfoveal choroidal thickness in new‐onset acute Vogt‐Koyanagi‐Harada disease
- 5 May 2022
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 50 (6) , 678-680
Prognostic value of subfoveal choroidal thickness in new‐onset acute Vogt‐Koyanagi‐Harada disease
- 24 September 2020
- Published by BMJ in British Journal of Ophthalmology
- Vol. 105 (11) , 1525-1533
Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet’s disease
Background To evaluate long-term efficacy of infliximab (IFX) in refractory uveoretinitis associated with Behçet’s disease (BD) depending on uveoretinitis duration. Methods Records of 16 patients with BD (32 eyes) followed for >5 years after starting IFX, were retrospectively reviewed. Long-term efficacy was compared between patients with short duration (≤18 months, n=7) versus long duration (>18 months, n=9) of their uveoretinitis prior to starting IFX. Results The median follow-up after starting IFX was 132 months (76–146 months). Mean frequency of attacks and the 1-year Behçet’s Disease Ocular Attack Score 24 decreased significantly over 10 years. Overall, the percentage of eyes with a best-corrected visual acuity (BCVA) ≥1.0 increased from 47% at baseline to 59% at 5 years; the percentage of eyes with a BCVA ≤0.1 was 19% at both baseline and 5 years. The frequency of ocular attacks decreased similarly in both short duration and long duration groups; however, the percentage of eyes with a BCVA ≥1.0 at 5 years was 100% in the short duration group versus 28% in the long duration group. IFX was discontinued in four patients with an excellent response to IFX therapy; all were young male patients in the short duration group with good BCVA bilaterally, and none had inflammatory recurrences over a median follow-up of 56 months off IFX. Conclusion Initiation of IFX therapy in patients with BD within 18 months of their uveoretinitis onset was more effective in maintaining good BCVA than after 18 months.
- 24 September 2020
- Published by BMJ in British Journal of Ophthalmology
- Vol. 105 (11) , 1525-1533
Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet’s disease
Background To evaluate long-term efficacy of infliximab (IFX) in refractory uveoretinitis associated with Behçet’s disease (BD) depending on uveoretinitis duration. Methods Records of 16 patients with BD (32 eyes) followed for >5 years after starting IFX, were retrospectively reviewed. Long-term efficacy was compared between patients with short duration (≤18 months, n=7) versus long duration (>18 months, n=9) of their uveoretinitis prior to starting IFX. Results The median follow-up after starting IFX was 132 months (76–146 months). Mean frequency of attacks and the 1-year Behçet’s Disease Ocular Attack Score 24 decreased significantly over 10 years. Overall, the percentage of eyes with a best-corrected visual acuity (BCVA) ≥1.0 increased from 47% at baseline to 59% at 5 years; the percentage of eyes with a BCVA ≤0.1 was 19% at both baseline and 5 years. The frequency of ocular attacks decreased similarly in both short duration and long duration groups; however, the percentage of eyes with a BCVA ≥1.0 at 5 years was 100% in the short duration group versus 28% in the long duration group. IFX was discontinued in four patients with an excellent response to IFX therapy; all were young male patients in the short duration group with good BCVA bilaterally, and none had inflammatory recurrences over a median follow-up of 56 months off IFX. Conclusion Initiation of IFX therapy in patients with BD within 18 months of their uveoretinitis onset was more effective in maintaining good BCVA than after 18 months.
- Open Access
- 29 July 2020
- Published by Taylor & Francis in Immunological Medicine
- Vol. 44 (2) , 86-97
Evaluation of disease activity in uveoretinitis associated with Behçet’s disease
Behçet’s disease is a multi-organ inflammatory disorder with systemic vasculitis of unknown etiology. Ocular lesions occur in about 70% of patients with Behçet’s disease, and it is more frequent and severe in men. The frequency of ocular inflammatory attacks has been used as a main outcome measure to assess the efficacy of therapy on uveoretinitis in patients with Behçet’s disease. The ocular Behçet’s disease research group of Japan have recently proposed a new scoring system, Behçet’s disease ocular attack score 24 (BOS24), to assess the disease activity of ocular Behçet’s disease. This review highlights the efficacy and application of the BOS24 scoring system in clinical practice for patients with ocular Behçet’s disease. In addition, a new semi-quantitative scoring system to evaluate the degree of retinal vascular leakage on fluorescein angiography reported by our group is described.
- 29 July 2020
- Published by Taylor & Francis in Immunological Medicine
- Vol. 44 (2) , 86-97
Open AccessEvaluation of disease activity in uveoretinitis associated with Behçet’s disease
Behçet’s disease is a multi-organ inflammatory disorder with systemic vasculitis of unknown etiology. Ocular lesions occur in about 70% of patients with Behçet’s disease, and it is more frequent and severe in men. The frequency of ocular inflammatory attacks has been used as a main outcome measure to assess the efficacy of therapy on uveoretinitis in patients with Behçet’s disease. The ocular Behçet’s disease research group of Japan have recently proposed a new scoring system, Behçet’s disease ocular attack score 24 (BOS24), to assess the disease activity of ocular Behçet’s disease. This review highlights the efficacy and application of the BOS24 scoring system in clinical practice for patients with ocular Behçet’s disease. In addition, a new semi-quantitative scoring system to evaluate the degree of retinal vascular leakage on fluorescein angiography reported by our group is described.
- 27 May 2020
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 29 (7-8) , 1520-1529
Effect of In Vivo Expansion of Regulatory T Cells with IL-2/anti-IL-2 Antibody Complex Plus Rapamycin on Experimental Autoimmune Uveoretinitis
Purpose: To determine the effect of injection of IL-2/anti-IL-2 antibody (IL-2 complex) together with rapamycin on the development of experimental autoimmune uveoretinitis (EAU). Methods: C57BL/6J mice were immunized with human interphotoreceptor retinoid-binding protein peptide. The immunized mice were injected intraperitoneally with PBS, IL-2 complex, rapamycin, or IL-2 complex/rapamycin on days 1, 2, 3, and 4 (induction phase) or days 10, 11, 12, and 13 (effector phase) after immunization. Results: Expansion of CD4+Foxp3+ regulatory T cells in draining lymph nodes was observed in IL-2 complex and IL-2 complex/rapamycin-treated mice. Although injection of IL-2 complex alone was not capable of decreasing the clinical score of EAU, injection of IL-2 complex/rapamycin significantly delayed the onset of EAU. In contrast, the treatment with IL-2 complex alone or IL-2 complex/rapamycin during effector phase failed to suppress EAU. Conclusions: These findings suggest the potential limitations of IL-2 complex or IL-2 complex/rapamycin during EAU.
- 27 May 2020
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 29 (7-8) , 1520-1529
Effect of In Vivo Expansion of Regulatory T Cells with IL-2/anti-IL-2 Antibody Complex Plus Rapamycin on Experimental Autoimmune Uveoretinitis
Purpose: To determine the effect of injection of IL-2/anti-IL-2 antibody (IL-2 complex) together with rapamycin on the development of experimental autoimmune uveoretinitis (EAU). Methods: C57BL/6J mice were immunized with human interphotoreceptor retinoid-binding protein peptide. The immunized mice were injected intraperitoneally with PBS, IL-2 complex, rapamycin, or IL-2 complex/rapamycin on days 1, 2, 3, and 4 (induction phase) or days 10, 11, 12, and 13 (effector phase) after immunization. Results: Expansion of CD4+Foxp3+ regulatory T cells in draining lymph nodes was observed in IL-2 complex and IL-2 complex/rapamycin-treated mice. Although injection of IL-2 complex alone was not capable of decreasing the clinical score of EAU, injection of IL-2 complex/rapamycin significantly delayed the onset of EAU. In contrast, the treatment with IL-2 complex alone or IL-2 complex/rapamycin during effector phase failed to suppress EAU. Conclusions: These findings suggest the potential limitations of IL-2 complex or IL-2 complex/rapamycin during EAU.
- 4 May 2020
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 22 (1) , 582-590
Anti‑inflammatory effects of the NF‑κB inhibitor dehydroxymethylepoxyquinomicin on ARPE‑19 cells
The retinal pigment epithelium (RPE) is a polarized, monolayer of pigmented cells that forms the outer retinal layer. A key function of the RPE is to maintain the integrity of the photoreceptors mainly via phagocytosis and recycling of the digested photoreceptor outer segments. Moreover, RPE cells are a major source of inflammatory cytokines and chemokines, which play important roles in the activation of other immune cells under inflammatory conditions in the posterior segment of the eye. Dehydroxymethylepoxyquinomicin (DHMEQ) is a NF‑κB inhibitor and its structure is related to that of epoxyquinomicin C, which is an antibiotic. The present study evaluated the anti‑inflammatory effects of DHMEQ on a human retinal pigment epithelial cell line (ARPE‑19). It was revealed that high concentrations of DHMEQ (100 µg/ml) induced apoptosis and necrosis of tumor necrosis factor (TNF)‑α‑stimulated ARPE‑19 cells. Furthermore, the percentage of intercellular adhesion molecule 1 (ICAM‑1)‑positive TNF‑α‑stimulated cells was significantly reduced in the presence of DHMEQ (10 µg/ml), as determined by flow cytometry. It was also demonstrated that DHMEQ exposure significantly decreased the levels of interleukin (IL)‑8 and monocyte chemoattractant protein‑1 (MCP‑1) in the supernatant of cultured ARPE‑19 cells as determined by ELISA. Moreover, the protein expression levels of IL‑8 and MCP‑1 were significantly reduced in ARPE‑19 cells exposed to DHMEQ compared with cells exposed to dexamethasone. PCR array analysis revealed that DHMEQ reduced the expression levels of MCP‑1, ICAM‑1, IL‑6, Toll‑like receptor (TLR)2, TLR3 and TLR4. Therefore, the present results indicated that DHMEQ has anti‑inflammatory effects on TNF‑α‑stimulated ARPE‑19 cells. Thus, DHMEQ may have therapeutic potential for TNF‑α‑mediated inflammatory disorders of the eye.
- 4 May 2020
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 22 (1) , 582-590
Anti‑inflammatory effects of the NF‑κB inhibitor dehydroxymethylepoxyquinomicin on ARPE‑19 cells
The retinal pigment epithelium (RPE) is a polarized, monolayer of pigmented cells that forms the outer retinal layer. A key function of the RPE is to maintain the integrity of the photoreceptors mainly via phagocytosis and recycling of the digested photoreceptor outer segments. Moreover, RPE cells are a major source of inflammatory cytokines and chemokines, which play important roles in the activation of other immune cells under inflammatory conditions in the posterior segment of the eye. Dehydroxymethylepoxyquinomicin (DHMEQ) is a NF‑κB inhibitor and its structure is related to that of epoxyquinomicin C, which is an antibiotic. The present study evaluated the anti‑inflammatory effects of DHMEQ on a human retinal pigment epithelial cell line (ARPE‑19). It was revealed that high concentrations of DHMEQ (100 µg/ml) induced apoptosis and necrosis of tumor necrosis factor (TNF)‑α‑stimulated ARPE‑19 cells. Furthermore, the percentage of intercellular adhesion molecule 1 (ICAM‑1)‑positive TNF‑α‑stimulated cells was significantly reduced in the presence of DHMEQ (10 µg/ml), as determined by flow cytometry. It was also demonstrated that DHMEQ exposure significantly decreased the levels of interleukin (IL)‑8 and monocyte chemoattractant protein‑1 (MCP‑1) in the supernatant of cultured ARPE‑19 cells as determined by ELISA. Moreover, the protein expression levels of IL‑8 and MCP‑1 were significantly reduced in ARPE‑19 cells exposed to DHMEQ compared with cells exposed to dexamethasone. PCR array analysis revealed that DHMEQ reduced the expression levels of MCP‑1, ICAM‑1, IL‑6, Toll‑like receptor (TLR)2, TLR3 and TLR4. Therefore, the present results indicated that DHMEQ has anti‑inflammatory effects on TNF‑α‑stimulated ARPE‑19 cells. Thus, DHMEQ may have therapeutic potential for TNF‑α‑mediated inflammatory disorders of the eye.
- 5 April 2019
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 28 (2) , 240-248
Anti-Inflammatory Effect of Dehydroxymethylepoxyquinomicin, a Nuclear factor–κB Inhibitor, on Endotoxin-Induced Uveitis in Rats In vivo and In vitro
Purpose: To determine the anti-inflammatory effects of dehydroxymethylepoxyquinomicin (DHMEQ), a nuclear factor-κB (NF-κB) inhibitor, on endotoxin-induced uveitis (EIU) in rats. Methods: EIU was induced by a subcutaneous injection of lipopolysaccharide (LPS) in Lewis rats. DHMEQ was injected intraperitoneally concurrently with the LPS. Aqueous humor was collected 24 h after the LPS injection. Isolated peritoneal exudate cells (PECs) were exposed to LPS with or without DHMEQ to determine the production of TNF-α, IL-6, and MCP-1. Results: DHMEQ significantly reduced the number of infiltrating cells, and the concentrations of proteins, TNF-α, and IL-6 in the aqueous humor. DHMEQ suppressed the production of TNF-α, IL-6, and MCP-1 from PECs. Immunochemistry revealed a reduction in the translocation of the NF-κB p65 into the nuclei in DHMEQ-exposed PECs. Conclusions: The results indicate that DHMEQ has anti-inflammatory effects on EIU and may be a promising agent to treat intraocular inflammation.
- 5 April 2019
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 28 (2) , 240-248
Anti-Inflammatory Effect of Dehydroxymethylepoxyquinomicin, a Nuclear factor–κB Inhibitor, on Endotoxin-Induced Uveitis in Rats In vivo and In vitro
Purpose: To determine the anti-inflammatory effects of dehydroxymethylepoxyquinomicin (DHMEQ), a nuclear factor-κB (NF-κB) inhibitor, on endotoxin-induced uveitis (EIU) in rats. Methods: EIU was induced by a subcutaneous injection of lipopolysaccharide (LPS) in Lewis rats. DHMEQ was injected intraperitoneally concurrently with the LPS. Aqueous humor was collected 24 h after the LPS injection. Isolated peritoneal exudate cells (PECs) were exposed to LPS with or without DHMEQ to determine the production of TNF-α, IL-6, and MCP-1. Results: DHMEQ significantly reduced the number of infiltrating cells, and the concentrations of proteins, TNF-α, and IL-6 in the aqueous humor. DHMEQ suppressed the production of TNF-α, IL-6, and MCP-1 from PECs. Immunochemistry revealed a reduction in the translocation of the NF-κB p65 into the nuclei in DHMEQ-exposed PECs. Conclusions: The results indicate that DHMEQ has anti-inflammatory effects on EIU and may be a promising agent to treat intraocular inflammation.
- Open Access
- 25 July 2017
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 19 (1) , 176
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
- 25 July 2017
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 19 (1) , 176
Open AccessInhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody